Display options
Cite
Kamel AY, Concepcion O, Schlachterman A, et al. Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease. ACG Case Rep J. 2016;3(3):187-9doi: 10.14309/crj.2016.45.
Kamel, A. Y., Concepcion, O., Schlachterman, A., Glover, S., & Forsmark, C. Y. (2016). Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease. ACG case reports journal, 3(3), 187-9. https://doi.org/10.14309/crj.2016.45
Kamel, Amir Y, et al. "Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease." ACG case reports journal vol. 3,3 (2016): 187-9. doi: https://doi.org/10.14309/crj.2016.45
Kamel AY, Concepcion O, Schlachterman A, Glover S, Forsmark CY. Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease. ACG Case Rep J. 2016 Apr 15;3(3):187-9. doi: 10.14309/crj.2016.45. eCollection 2016 Apr. PMID: 27144200; PMCID: PMC4843152.
Copy Download .nbib Format: NLM
Share it on

ACG Case Rep J. 2016 Apr 15;3(3):187-9. doi: 10.14309/crj.2016.45. eCollection 2016 Apr.

Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease.

ACG case reports journal

Amir Y Kamel, Orestes Concepcion, Alexander Schlachterman, Sarah Glover, Christopher Y Forsmark

Affiliations

  1. Department of Pharmacy, University of Florida, Gainesville, FL.
  2. Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, FL.

PMID: 27144200 PMCID: PMC4843152 DOI: 10.14309/crj.2016.45

Abstract

We present a 29-year-old male with Crohn's disease who developed chronic inflammatory demyelinating polyneuropathy (CIDP) related to infliximab therapy. He developed lower extremity weakness and dysesthesia 3 weeks after a fourth infliximab dose. Laboratory examination revealed an elevated cerebrospinal fluid protein without pleocytosis. The patient initially responded to plasmapheresis therapy with marked symptomatic improvement, but relapsed and was refractory to subsequent treatments with plasmaphereisis, intravenous immunoglobulin, and glucocorticoids. While a causal relationship between infliximab and CIDP cannot be proven, clinicians should monitor Crohn's disease patients who are receiving TNF-α antagonists for neurologic symptoms suggestive of demyelinating disease.

References

  1. Muscle Nerve. 2010 May;41(5):723-7 - PubMed
  2. Inflamm Bowel Dis. 2008 Mar;14(3):389-95 - PubMed
  3. Expert Rev Anti Infect Ther. 2003 Dec;1(4):597-608 - PubMed
  4. J Peripher Nerv Syst. 2006 Mar;11(1):30-46 - PubMed
  5. N Engl J Med. 1997 Oct 9;337(15):1029-35 - PubMed
  6. Arthritis Rheum. 2006 May;54(5):1429-34 - PubMed
  7. Scand J Gastroenterol. 1991 Feb;26(2):219-24 - PubMed
  8. J Exp Med. 2001 Feb 19;193(4):427-34 - PubMed
  9. Res Immunol. 1997 Jun;148(5):307-12 - PubMed
  10. Nat Rev Neurol. 2011 Aug 16;7(9):507-17 - PubMed
  11. Rheumatology (Oxford). 2013 May;52(5):868-74 - PubMed
  12. South Med J. 1997 Jun;90(6):606-10 - PubMed
  13. Electromyogr Clin Neurophysiol. 2010 Apr-Jun;50(3-4):181-5 - PubMed
  14. Gastroenterology. 2004 Jan;126(1):19-31 - PubMed
  15. Neurology. 1995 Mar;45(3 Pt 1):416-21 - PubMed
  16. J Exp Med. 1997 May 5;185(9):1573-84 - PubMed
  17. Arch Neurol. 1989 Aug;46(8):878-84 - PubMed
  18. Brain. 2005 Apr;128(Pt 4):867-79 - PubMed
  19. Muscle Nerve. 2008 Mar;37(3):281-92 - PubMed
  20. Int J Colorectal Dis. 2009 May;24(5):603-4 - PubMed

Publication Types